GlobeNewsWire
03 Nov 2025, 12:00 UTC · 48w ago
Verdict
Headline takes no side. We score ARVN +0.80 across three claims — strongly bullish.
+0.80strongly bullish
More positive than 87% of ticker scores this week
Scored by the NIS engine · methodology.
Search tags
What the story claims
3 claims · scored −1 bearish … +1 bullish
The FDA has approved VEPPANU™ (vepdegestrant) for the treatment of ESR1m, ER+/HER2- breast cancer.
More positive than 99% of claims this week
VEPPANU™ is the first-ever FDA-approved PROTAC (proteolysis targeting chimera) drug.
Continue reading
5 related stories
More positive than 93% of claims this week
Arvinas management will participate in two upcoming investor conferences.
More positive than 44% of claims this week
Which stocks this story touches
More positive than 87% of ticker scores this week
The company received FDA approval for VEPPANU, a first-ever approved PROTAC, supporting its pipeline development.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
−27.6%
Price is moving against the score
$7.34 vs $10.14 close before publication (Oct 31) · not market-adjusted
ARVN chart →
